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Abstract
Background: Adherence to care and treatment are essential for HIV-infected individuals to benefit from
antiretroviral therapy (ART). We sought to quantify the effects on treatment outcomes of missing visits soon after
initiating ART.
Methods: We analyzed data from HIV-infected patients initiating ART at Themba Lethu Clinic, Johannesburg, South
Africa, from April 2004 to August 2008. We used log-binomial regression to evaluate the relative risk of missing
visits during the first six months of ART on immunological response and virologic suppression. Cox models were
used to evaluate the relationship between missed visits and mortality and loss to follow up over 12 months.
Results: Of 4476 patients, 65% missed no visits, while 26% missed one visit, 7% missed two and 1.6% missed three
or more visits during the first six months on treatment. Patients who missed three or more medical or antiretroviral
(ARV) visits had a two-fold increased risk of poor CD4 response by six months, while the risk of failing to achieve
virologic suppression by six months increased two- to five-fold among patients who missed two and three or
more medical or ARV visits. Adjusted Cox models showed that patients who missed two (HR 2.1; 95% CI: 1.0-4.3)
and three or more (HR 4.7; 95% CI: 1.4-16.2) medical visits had an increased risk of death, while those who missed
two ARV (HR 3.8; 95% CI: 2.5-5.8) or three or more medical (HR 3.0; 95% CI: 1.1-8.1) visits had an increased risk of
loss to follow up.
Conclusions: Thirty-five percent of patients missed one or more visits in the first six months on treatment,
increasing their risk of poorer outcomes. These patients could be targeted for additional adherence counselling to
help improve ART outcomes.
Background
Expansion of antiretroviral therapy (ART) treatment
programmes in resource-limited settings has helped to
substantially improve patient outcomes on ART [1];
however, programmatic outcomes, such as death and
loss to follow up, still remain high when compared with
industrialized countries [2-4].
In order to help improve overall treatment outcomes,
treatment providers need to focus retention efforts on
ART patients who are at increased risk of poor clinical
outcomes and becoming lost to follow up. HIV clinics
in resource-limited settings continue to struggle to keep
patients in care and adhering to treatment in the early
stages of ART [4-8], with high mortality among patients
who leave care [9,10]. Adhering to the required treat-
ment schedule early on in care can be difficult, but may
be an important step in maintaining long-term reten-
tion, adherence and reductions in morbidity and mortal-
ity. Previous studies have shown that poor adherence to
treatment regimens [11-13] and medical appointments
soon after initiating treatment can decrease the overall * Correspondence: abrennan@bu.edu
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any medium, provided the original work is properly cited.effectiveness of ART [14-21], but it is not clear if these
early missed visits have any longer term effects.
Because late presentation for ART is so common [22],
identifying patients who are not attending scheduled
clinic appointments on time and developing strategies
directed at keeping them in care and adhering to treat-
ment is critical to improving long-term outcomes.
Although several studies have looked at the association
between missed visits and patient outcomes, few have
evaluated this relationship in a resource-limited setting
and none have looked at the long-term effects of missed
visits early on in treatment. We hypothesized that those
HIV-positive patients, who miss visits in the first six
months of treatment, but return to care, will be at
increased risk of death and loss to follow up, and have
poorer immunological and virologic outcomes when
compared with patients with perfect appointment
attendance.
Methods
Cohort description
This retrospective cohort study was conducted in the
Themba Lethu Clinic in Johannesburg, South Africa.
Themba Lethu is one of thel a r g e s tA R Tc l i n i c si n
South Africa, with more than 26,500 patients enrolled in
care since April 2004, more than 17,700 of whom have
initiated ART. The clinic staff provides care according
to South African national Department of Health guide-
lines [23]. Patient data used in this analysis is extracted
from an electronic patient record system, called Thera-
pyEdge-HIV™.
Use of Themba Lethu Clinic data was approved by the
Human Research Ethics Committee of the University of
the Witwatersrand. Approval for analysis of the data in
a de-identified manner was granted by the Institutional
Review Board of Boston University.
Eligibility criteria
Our analysis included HIV-positive patients who were
eligible for ART based on the 2004 South African
national treatment guidelines [23]. Eligible subjects
were ART naïve and ≥18 years of age, with a baseline
CD4 count at ART initiation of ≤200 cells/mm
3 and
initiated onto standard government first-line ART regi-
mens of stavudine (d4T) or zidovudine (AZT) with
lamivudine (3TC) and either efavirenz (EFV) or nevira-
pine (NVP) between April 2004 and August 2008. We
further excluded pregnant women, those who had less
than three scheduled medical and three scheduled
antiretroviral (ARV) pickup visits during the first six
months of ART, and patients with less than 21 months
of potential follow-up time (see section on person-
time).
Study variables
We evaluated the relationship between missed medical
and ARV pickup visits within the first six months after
initiating ART on four outcomes: (1) mortality; (2) loss
to follow up; (3) immunologic response; and (4) virolo-
gic suppression. Loss to follow up was defined as not
having been to the clinic for at least four months. Data
on mortality, including for those patients who are lost
to follow up, is verified with the South African National
Vital Registration Infrastructure Initiative [24-26]. Poor
immunological response was defined as an increase of
<50 cells/mm
3 by six months on ART, while failure to
achieve virologic suppression was defined as a viral load
of ≥400 copies/ml by six months on ART. When CD4
values were missing, they were interpolated by taking
the mean of the proceeding and following measures
when both were available (6%).
Missing medical and ARV pickup visits during the
first six months of initiating first-line ART was the pri-
mary independent variable. After ART initiation, ARV
visits are scheduled monthly, while medical visits are
booked at months one, four and five. Patients prescribed
nevirapine are scheduled for two additional medical vis-
its at two weeks and two months to monitor for liver
toxicity. Thus, in the first six months on treatment,
patients can have up to five ARV visits (the first is
excluded as it is the date of ART initiation) and between
three and five scheduled medical visits. Unscheduled vis-
its were not counted in the exposure variable since the
exposure of interest is missing a scheduled visit, so any
non-scheduled visit could not be missed.
We determined each participant’s missed visit status
by evaluating appointment attendance records. Appoint-
ment scheduling is managed with the TherapyEdge-
HIV™ database, which is used to schedule all visits and
to record the actual date on which a scheduled visit was
completed. As patients are given two extra days worth
of pills each month in case they cannot attend their
scheduled ARV visits on time, it is thus likely that in
the first six months on treatment, patients who are
more than seven days late for a pickup would be with-
out medication. Accordingly, we defined a missed visit
as being at least seven days late for that scheduled visit.
For our primary analysis, missed visit status over the
first six months of initiating ART was categorized as
patients who missed 0, 1, 2 and ≥3 visits. We analyzed
missed visits stratified by type of visit as either medical
or ARV drug pickup.
For death and loss to follow up analyses (the only two
time-to-event analyses), person-time accrued from nine
months after treatment initiation. We chose the period
of nine months in order to exclude any deaths or losses
to follow up that occurred during exposure (missed
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additional three months in order to reduce the impact
of reverse causality (i.e., death causing patients to miss
visits). Person-time accrued until the earliest of: (1) date
of death; (2) date of loss to follow up; (3) date of trans-
fer; or (4) completion of 12 additional months of follow
up.
Statistical analysis
Descriptive statistics were performed to look for baseline
differences in the distribution of missed visits. Log-bino-
mial regression was used to evaluate predictors asso-
ciated with missing a visit during the first six months of
initiating ART. We also estimated the relative risk of
missing a visit in the first six months on both poor CD4
response (increase of <50 cells/mm
3) and failure to
achieve virologic suppression (< 400 copies/mL) by six
months on ART. Log-binomial models were adjusted for
age, sex, WHO stage III/IV condition, body mass index
(BMI), baseline haemoglobin and baseline CD4 count
(categorized ≤50, 51-100 and 101-200 cell/mm
3)a n d
baseline ART regimen (AZT vs. d4T and NVP vs. EFV).
We estimated crude and adjusted hazard ratios of mor-
tality and loss to follow up by missed visit status using
Cox proportional hazards models. Hazard models were
also adjusted for age, sex, baseline regimen, total num-
ber of scheduled visits and CD4 count by the ninth
month of ART.
Results
Out of 10,048 patients aged 18 years or older who
initiated ART between April 2004 and August 2008
w i t hC D 4c o u n t so f< 2 0 0c e l l s / m m
3, we excluded 1292
not on standard first-line ART, 1205 non-naïve patients,
109 women pregnant at baseline, 1875 patients who did
not have the necessary six months of exposure or died
prior to nine months of ART, and 1091 patients who
did not have at least three medical and three scheduled
ARV visits in the first six months of treatment. This left
4476 patients eligible for this analysis.
Baseline demographics and clinical characteristics
show that patients had a median baseline CD4 count of
76 cells/mm
3 (IQR 28-136 cells/mm
3), were predomi-
nately female (62.8%), had a median age of 36.1 years
(IQR 31.3-42.2), and were typically prescribed d4T-3TC-
EFV (89.4%) as a baseline regimen (Table 1). Those who
missed 1, 2 or ≥3 visits (ARV or medical) in the first six
months on ART were similar in baseline demographic
and clinical characteristics to those who missed none,
with the exception of having a higher proportion of
men. Additionally, patients who missed ≥3 visits had a
higher percentage of patients older than 25 years and
more patients on NVP- and AZT- based regimens when
compared with the other three groups.
Among 4476 patients initiating ART, 65.1% (n = 2913)
attended all scheduled medical and ARV visits, 1178
(26.3%) missed one visit, 312 (7.0%) missed two visits,
and 73 (1.6%) missed three or more visits during the
first six months on treatment. Patients had a median of
four (IQR 3-5) scheduled medical visits and a median of
five (IQR 4-5) scheduled ARV pickup visits. There were
a total of 115 deaths (2.6%) and 277 patients were lost
to follow up (6.2%) during the 12 months of observa-
tion. Median follow-up time (which began nine months
after ART initiation) among patients who died and
missed 0, 1, 2 and ≥3 visits (medical or ARV) was 4.5
months (IQR 1.8-9.2), 5.7 months (IQR 2.8-9.8), 3.5
months (IQR 2.0-6.8) and 2.2 months (IQR 0.6-3.5),
respectively. Median follow-up time among patients who
were lost to follow up and who missed 0, 1, 2 and ≥3
visits (medical or ARV) was 6.5 months (IQR 3.8-8.8),
7.1 months (IQR 3.9-9.4), 5.4 months (IQR 3.2-7.6) and
6.3 months (IQR 3.2-8.9), respectively.
Predictors of missed visits within the first six months of
treatment
Using log-binomial regression, we identified no strong
independent predictors of missing a medical or ARV
visit in the first six months on ART. We found that
males, younger patients and those with BMI of <17.5
had a somewhat increased risk of missing a visit in the
first six months (Table 2). Patients on an AZT-based
regimen (vs. d4T) (RR 1.1; 95% CI 0.8-1.4) and those
on a NVP-based regimen (vs. EFV) (RR 1.2; 95% CI
1.0-1.4) had an increased risk of missing a medical
visit early on in treatment. While not perfectly consis-
tent, baseline CD4 count was not predictive of missing
a medical or ARV visit during the first six months of
ART.
CD4 count response and viral load suppression
In adjusted models, we found that patients who missed
three or more medical visits had the highest risk of poor
CD4 response by six months on ART (RR 2.3; 95% CI:
1.4-3.8) (Table 3). Male patients and those on AZT-
based regimens (vs. d4T) were also at increased risk of
poor CD4 response, while patients younger than 50
years of age were less likely to have had a poor CD4
response in the first six months on ART compared with
patients 50 years of age or older. Patients who missed 2
and ≥3 medical (RR 2.3; 95% CI: 1.5-3.4 and RR 3.0;
95% CI: 1.3-7.1, respectively) or ARV visits (RR 1.9; 95%
CI: 1.1-3.3 and RR 5.8; 95% CI: 3.0-11.1, respectively)
were at increased risk of failing to achieve viral suppres-
sion by six months on treatment compared with patients
who attended all scheduled visits. Although not signifi-
cant, patients younger than 25 years of age and those on
an AZT-based regimen (vs. d4T) or NVP-based regimen
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stratified by missed visit status in the first six months of ART (n = 4476)
Missed visit status
(Medical or ARV)
Characteristics 0 1 2 ≥ 3 Total
(n = 2913) (n = 1178) (n = 312) (n = 73) (n = 4476)
N (%) N (%) N (%) N (%) N (%)
Sex
Female 1870 (64.2%) 724 (61.5%) 179 (57.4%) 37 (50.7%) 2810 (62.8%)
Male 1043 (35.8%) 454 (38.5%) 133 (42.6%) 36 (49.3%) 1666 (37.2%)
Age at ART initiation
18-24.9 125 (4.3%) 60 (5.1%) 13 (4.2%) 7 (9.6%) 205 (4.6%)
25-29.9 427 (14.7%) 165 (14.0%) 50 (16.0%) 12 (16.4%) 654 (14.6%)
30-39.9 1390 (47.7%) 561 (47.6%) 149 (47.8%) 35 (48.0%) 2135 (47.7%)
40-49.9 714 (24.5%) 287 (24.4%) 79 (25.3%) 14 (19.2%) 1094 (24.4%)
≥ 50 257 (8.8%) 105 (8.9%) 21 (6.7%) 5 (6.9%) 388 (8.7%)
CD4 at ART initiation (cells/mm
3)
0-50 1069 (36.7%) 433 (36.8%) 121 (38.8%) 26 (35.6%) 1649 (36.8%)
51-100 680 (23.3%) 266 (22.6%) 62 (19.9%) 16 (21.9%) 1024 (22.9%)
101-200 1123 (38.6%) 464 (39.4%) 128 (41.0%) 30 (41.1%) 1745 (39.0%)
Missing 41 (1.4%) 15 (1.3%) 1 (0.3%) 1 (1.4%) 58 (1.3%)
WHO stage at ART initiation
I/II 1485 (51.0%) 570 (48.4%) 169 (54.2%) 33 (45.2%) 2257 (50.4%)
III 1183 (40.6%) 496 (42.1%) 122 (39.1%) 33 (45.2%) 1834 (41.0%)
IV 245 (8.4%) 112 (9.5%) 21 (6.7%) 7 (9.6%) 385 (8.6%)
First-line ART regimen
d4T/3TC/EFV 2614 (89.7%) 1053 (89.4%) 280 (89.7%) 55 (75.3%) 4002 (89.4%)
d4T/3TC/NVP 219 (7.5%) 95 (8.1%) 24 (7.7%) 13 (17.8%) 351 (7.8%)
AZT/3TC/EFV 75 (2.6%) 28 (2.4%) 8 (2.6%) 5 (6.9%) 116 (2.6%)
AZT/3TC/NVP 5 (0.2%) 2 (0.2%) 0 (0%) 0 (0%) 7 (0.7%)
Outcomes by sixth month of ART
Poor CD4 response
(increase <50 cells/mm
3)
509 (17.5%) 230 (19.5%) 60 (19.2%) 21 (28.8%) 820 (18.3%)
Failure to achieve VL
suppression (< 400copies/mL)
191 (6.6%) 80 (6.8%) 34 (10.9%) 11 (15.1%) 316 (7.1%)
Outcomes by 12 months of follow up (21 months of ART)
Death 71 (2.4%) 32 (2.7%) 6 (2.0%) 6 (8.2%) 115 (2.6%)
Loss to follow up 174 (6.0%) 65 (5.5%) 27 (8.7%) 11 (15.1%) 277 (6.2%)
Transferred 60 (2.1%) 37 (3.1%) 6 (2.0%) 1 (1.0%) 104 (2.3%)
Alive and in care 2608 (89.5%) 1044 (88.6%) 273 (87.5%) 55 (75.3%) 3980 (89.0%)
Characteristics 0 1 2 ≥ 3 Total
Median (IQR) Median (IQR) Median (IQR) Median (IQR) Median (IQR)
CD4 at ART initiation (cells/mm
3) 76 (29-137) 77 (28-136) 72 (25-136) 82.5 (20.5-133.5) 76 (28-136)
CD4 nine months after ART initiation (cells/mm
3) 245 (175-334 238 (176-323) 240 (177-303) 221 (151-319) 243 (175-328)
Time on ART (months) 28.4 (11.8-33.3) 30.3 (18.0-36.3) 30.8 (19.8-39.5) 25.6 (15.4-40.2) 25.6 (15.4-50.2)
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fied by missed visit status in the first six months of ART (n = 4476) (Continued)
Hb at ART initiation (ug/dL) 11.4 (10.0-12.9) 11.5 (10.1-13.0) 11.7 (9.9-13.1) 11.7 (10.3-13.0) 11.5 (10.0-12.9)
BMI at ART initiation 21.4 (19.0-24.4) 21.2 (18.8-24.3) 21.4 (19.4-24.2) 20.6 (18.6-22.6) 21.4 (19.0-24.3)
Age at ART initiation 36.1 (31.3-42.2) 36.1 (31.4-42.1) 35.4 (31.5-42.1) 35.7 (29.5-40.0) 36.1 (31.3-42.2)
Total medical visits scheduled in first six months of ART 4 (4-5) 4 (3-5) 4 (3-5) 4 (3-5) 4 (3-5)
Total ARV visits scheduled in first six months of ART 5 (4-6) 5 (4-5) 5 (4-5) 4 (4-5) 5 (4-5)
ART, antiretroviral therapy; ARV, antiretroviral; Hb, haemoglobin; BMI, body mass index; d4T, stavudine; 3TC, lamivudine; EFV, efavirenz; NVP, nevirapine; IQR,
interquartile range
Table 2 Crude and adjusted predictors of missing a medical or ARV visit in the first six months on ART in
Johannesburg, South Africa (n = 4476)
Medical visits ARV visits
Variable Crude RR
(95% CI)
Adjusted RR
†
(95% CI)
Crude RR
(95% CI)
Adjusted RR
†
(95% CI)
Sex Female Reference Reference Reference Reference
Male 1.15 (1.05-1.27) 1.16 (1.05-1.28) 1.14 (1.03-1.28) 1.15 (1.02-1.28)
Baseline BMI ≥17.5 Reference Reference Reference Reference
< 17.5 1.11 (1.00-1.24) 1.09 (0.97-1.22) 1.24 (1.09-1.40) 1.22 (1.08-1.39)
Age at ART initiation ≥ 50 Reference Reference Reference Reference
40-49.9 1.11 (0.92-1.35) 1.15 (0.94-1.40) 1.00 (0.80-1.25) 1.00 (0.80-1.26)
30-39.9 1.04 (0.87-1.25) 1.07 (0.89-1.30) 1.08 (0.88-1.33) 1.08 (0.87-1.33)
25-29.9 1.07 (0.87-1.32) 1.10 (0.89-1.37) 1.01 (0.80-1.29) 1.03 (0.81-1.32)
18-24.9 1.10 (0.83-1.45) 1.13 (0.86-1.51) 1.22 (0.91-1.65) 1.23 (0.90-1.67)
Baseline CD4 count
(cells/mm
3)
100-200 Reference Reference Reference Reference
51-100 0.89 (0.78-1.01) 0.88 (0.77-1.00) 0.93 (0.81-1.08) 0.95 (0.83-1.07)
0-50 vs. 1.00 (0.90-1.12) 0.98 (0.88-1.09) 0.99 (0.88-1.12) 0.93 (0.80-1.07)
Baseline Hb (ug/dL) ≥ 10.0 Reference Reference Reference Reference
< 10.0 1.01 (0.91-1.13) 1.02 (0.92-1.14) 1.00 (0.89-1.14) 1.00 (0.88-1.13)
Baseline WHO stage I/II Reference Reference Reference Reference
III/IV 1.04 (0.94-1.14) 1.03 (0.93-1.14) 1.06 (0.95-1.19) 1.03 (0.92-1.16)
Baseline NRTI d4T Reference Reference Reference Reference
AZT 1.13 (0.86-1.48) 1.10 (0.84-1.44) 0.99 (0.71-1.39) 0.98 (0.70-1.38)
Baseline NNRTI EFV Reference Reference Reference Reference
NVP 1.13 (0.96-1.33) 1.18 (1.00-1.40) 1.04 (0.85-1.26) 1.05 (0.86-1.29)
†Relative risks (RR) are from a log-binomial regression model also adjusted for baseline BMI, age, baseline CD4, baseline haemoglobin, baseline WHO stage and
baseline regimen
CI, confidence interval; ART, antiretroviral therapy; BMI, body mass index; Hb, haemoglobin; d4T, stavudine; AZT, zidovudine; EFV, efavirenz; NVP, nevirapine; NRTI,
nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor
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Page 5 of 10Table 3 Relationship between missing an HIV treatment visit in the first six months of ART and poor CD4 response
and failure to suppress viral load in Johannesburg, South Africa (n = 4476)
Visits ARV Medical visits
Poor CD4 response
¥
Crude RR
(95% CI)
Adjusted RR
£
(95% CI)
Crude RR
(95% CI)
Adjusted RR
£
(95% CI)
Missed visit status
1 vs. 0 1.02 (0.88-1.19) 1.02 (0.87-1.18) 1.15 (1.00-1.33) 1.12 (0.98-1.29)
2 vs. 0 1.36 (0.99-1.85) 1.33 (0.98-1.80) 1.22 (0.90-1.65) 1.19 (0.89-1.61)
≥ 3 vs. 0 1.24 (0.37-4.14) 1.62 (0.49-5.34) 2.11 (1.91-3.74) 2.27 (1.35-3.83)
Age at initiation
18-24.9 vs. ≥50 0.46 (0.31-0.69) 0.52 (0.35-0.78) 0.46 (0.31-0.69) 0.52 (0.34-0.77)
25-29.9 vs. ≥50 0.56 (0.43-0.72) 0.62 (0.48-0.79) 0.56 (0.43-0.72) 0.61 (0.48-0.79)
30-39.9 vs. ≥50 0.69 (0.57-0.83) 0.73 (0.61-0.88) 0.69 (0.57-0.83) 0.73 (0.60-0.88)
40-49.9 vs. ≥50 0.82 (0.67-1.01) 0.84 (0.69-1.02) 0.82 (0.67-1.01) 0.83 (0.68-1.02)
Baseline CD4 count (cells/mm
3)
51-100 vs. 100-200 0.76 (0.65-0.89) 0.76 (0.65-0.89) 0.76 (0.65-0.89) 0.77 (0.64-0.88)
0-50 vs. 100-200 0.68 (0.59-0.78) 0.68 (0.59-0.79) 0.68 (0.59-0.78) 0.68 (0.60-0.79)
Baseline NRTI
AZT vs. d4T 1.41 (0.80-2.49) 1.42 (0.81-2.50) 1.41 (0.80-2.49) 1.46 (0.83-2.57)
Baseline NNRTI
NVP vs. EFV 0.84 (0.66-1.08) 0.92 (0.72-1.18) 0.84 (0.66-1.08) 0.93 (0.73-1.19)
Sex
Male vs. female 1.40 (1.24-1.58) 1.33 (1.18-1.51) 1.40 (1.24-1.58) 1.32 (1.17-1.50)
Failure to suppress viral load
€
Missed visit status
1 vs. 0 1.15 (0.89-1.50) 1.19 (0.89-1.51) 1.24 (0.97-1.58) 1.23 (0.96-1.57)
2 vs. 0 2.09 (1.33-3.29) 1.93 (1.12-3.32) 2.18 (1.47-3.24) 2.28 (1.54-3.36)
≥ 3 vs. 0 4.35 (1.71-11.0) 5.75 (2.97-11.1) 3.19 (1.34-7.58) 3.00 (1.28-7.06)
Age at initiation
18-24.9 vs. ≥50 1.64 (0.98-2.74) 1.55 (0.90-2.73) 1.64 (0.98-2.74) 1.41 (0.83-2.38)
25-29.9 vs. ≥50 1.13 (0.73-1.77) 1.01 (0.62-1.64) 1.13 (0.73-1.77) 0.96 (0.61-1.52)
30-39.9 vs. ≥50 0.98 (0.66-1.46) 0.99 (0.65-1.50) 0.98 (0.66-1.46) 0.92 (0.62-1.36)
40-49.9 vs. ≥50 0.92 (0.60-1.40) 0.93 (0.58-1.47) 0.92 (0.60-1.40) 0.85 (0.56-1.31)
Baseline CD4 count (cells/mm
3)
51-100 vs. 100-200 0.97 (0.74-1.20) 0.96 (0.70-1.30) 0.97 (0.74-1.20) 0.99 (0.75-1.30)
0-50 vs. 100-200 0.93 (0.74-1.29) 0.94 (0.72-1.24) 0.93 (0.74-1.29) 0.92 (0.72-1.19)
Baseline NRTI
AZT vs. d4T 1.41 (0.80-2.49) 1.69 (0.93-3.05) 1.41 (0.80-2.49) 1.60 (0.93-2.75)
Baseline NNRTI
NVP vs. EFV 0.79 (0.56-1.12) 1.12 (0.75-1.67) 0.79 (0.56-1.12) 1.22 (0.86-1.73)
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Page 6 of 10(vs. EFV) were also at increased risk of failing to achieve
viral load suppression by six months.
Mortality and loss to follow up
Adjusted multivariable Cox proportional hazards analy-
sis showed that more missed visits were generally asso-
ciated with increased risk of death and loss to follow up
over 12 months of follow up (which began nine months
after ART initiation) (Table 4). In terms of mortality,
patients who missed 2 and ≥3m e d i c a lv i s i t sh a dm o r e
than a two- to four-fold increased risk. The risk
increased to eight-fold (HR 8.2; 95% CI: 2.0-33.7) for
patients who missed ≥3 ARV visits, although it was esti-
m a t e dw i t hw i d ec o n f i d e n c ei n t e r v a l s .W es a wn o
increased risk of death among those who missed one
medical or ARV visit versus those who missed none.
Patients who missed 2 and ≥3 medical or ARV visits
also had a nearly two- to four-fold increased risk of
becoming lost during the follow up period. As with
death, missing one medical or ARV visit was not
strongly associated with an increased risk of becoming
lost to follow up.
Discussion
Recent estimates state that 5.2 million HIV-positive peo-
ple have initiated ART in resource-limited settings, an
increase of 1.2 million since the end of 2008 [27]. Initi-
ating this many patients onto care in such a short time
is a remarkable achievement, but is not without its chal-
lenges. Keeping these patients in care and adherent to
treatment, especially in the early stages of ART, is chal-
lenging the world over, and appears to be particularly
difficult in resource-limited settings. In our study, more
than 35% of patients attending the Themba Lethu Clinic
in Johannesburg, South Africa, failed to attend at least
one clinic visit on time in the first six months of treat-
ment. This finding is consistent with previous reports,
from industrialized countries, documenting 25%-44% of
recently diagnosed HIV-infected individuals failing to
adhere to scheduled visits early on in their care or treat-
ment [28-32]. Close to 10% of the cohort missed two or
more medical or ARV visits in the first six months of
ART, and this was strongly associated with negative
outcomes.
Documenting the amount of missed visits early on in
treatment is critical because of its potential implications
for poorer treatment outcomes. Previous studies have
shown that patients who miss visits soon after initiating
ART are at increased risk of early mortality and loss
[16,17]. In our study, patients who were unable to
adhere to clinic visits early on in treatment, but
returned to care, were at increased risk of poorer ART
outcomes (death and loss to follow up) over 12 months
of follow up beginning after a full nine months on treat-
m e n t ,p a r t i c u l a r l yi ft h e ym i s s e dm o r et h a no n ev i s i t .
This suggests that missing visits early is a marker for
those who will have poorer outcomes even if returning
to care. Our data are not able to elucidate the specific
mechanisms by which missing visits lead to poorer out-
c o m e s ,b u ti ti sl i k e l yt h a tt h i si sam a r k e rf o rp o o r
adherence.
Our results show that patients who miss visits early on
in care are less likely to achieve virologic suppression
after six months of ART compared with patients who
attended all scheduled visits. As adherence is critical to
the success of their treatment [11-13], missing medical
or ARV collection visits could compromise the continu-
ous supply of ART required to achieve long-term viral
suppression. Poor adherence to treatment as a result of
missing visits could result in failure to initially suppress
the virus [14,15,17,20] or cause a viral load rebound
[19], putting an individual at risk of drug resistance [13].
Our results also support previous research showing that
older patients mount poorer CD4 cell count responses
[33], but are more likely to adhere to clinic visits [34]
and achieve virologic suppression [33,34] compared with
their younger counterparts.
Alternatively, some of the relationship between missed
visits and poor treatment outcomes may result from
missed opportunities to detect and treat opportunistic
infections. These conditions may still be diagnosed and
treated at a later time, but opportunistic infections after
initiation of ART are associated with poor immune
recovery [35,36]. A longer period of time spent at a
lower CD4 count has been shown to increase patients’
overall risk of mortality [36,37]. Our finding that
patients who miss visits early on in care have a poorer
CD4 response supports this point further.
Table 3 Relationship between missing an HIV treatment visit in the first six months of ART and poor CD4 response
and failure to suppress viral load in Johannesburg, South Africa (n = 4476) (Continued)
Sex
Male vs. female 0.81 (0.65-1.01) 0.80 (0.60-1.04) 0.81 (0.65-1.01) 0.85 (0.67-1.07)
£ Relative risks (RR) are from a log-binomial regression model also adjusted for baseline haemoglobin, baseline WHO stage and baseline body mass index
¥ Poor CD4 response defined as an increase of <50 cells/mm3 by six months on ART
€ Failure to suppress viral load defined as a viral load ≥400 copies/ml by six months on ART
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are likely to be multi-factorial and complex. While we
found no strong predictors of missing medical visits, our
findings show that male gender, younger age, low base-
line BMI, AZT-based versus d4T- and NVP-based ver-
sus EFV-based regimens are predictive of missing visits
early on in treatment. Data from industrialized countries
has shown that younger patients [14,28,29,38], those
with poorer education [38] and those with low socio-
economic status [29] were more likely to miss visits
related to their HIV, but there is little evidence from
resource-limited settings. While not perfectly consistent
[18], most studies on the topic have shown that heal-
thier patients were more likely than sicker ones to miss
scheduled appointments [28-31]. Surprisingly, we did
not detect a relationship between CD4 count and
missed visits in our population. Distrust in the health-
care system, stigmatization of those infected by their
communities and patient financial constraints could also
play a major role in how adherent patients are to visit
schedules in a resource-limited setting [39]. In sub-
Saharan Africa, the cost of seeking care, even when
treatment is provided at no cost, can be an important
barrier to staying in care [40].
Our study is one of the first to report on the specific
relationship between missed visits in the first six months
of ART and clinical HIV treatment outcomes in a
resource-limited setting and longer term outcomes. Still,
our findings should be considered alongside the study’s
limitations. First, because our study reports data from a
single government HIV clinic, our results may not be
generalizable to the overall population. Second, data on
specific reasons for missed visits is not collected and
therefore we could not determine what the major bar-
riers are to maintaining a consistent schedule of care
and treatment.
Finally, we did not have actual ARV drug dispensing
data, and while missing scheduled drug collection visits
is likely to mean that a patient is without medication,
we cannot rule out the possibility that the individuals
were dispensed additional months of drug supplies.
H o w e v e r ,i nt h i ss t u d yw ec o n s i d e r e do n l yv i s i t si nt h e
first six months after treatment initiation, a period when
the pharmacy is least likely to dispense several months
of medication. This is also a period when a patient
needs to see a clinician in order to have his or her ARV
prescription renewed, and so we anticipate that this
occurred infrequently.
Conclusions
Our results suggest that patients who miss multiple vis-
its in the earliest period of treatment but remain in care
are at increased risk of poorer ART outcomes. Cur-
rently, a substantial proportion of funding and man-
power in resource-limited settings is focused on
reducing mortality and loss to follow up among those
started on ART. Our findings suggest that targeting
those who miss visits early on in treatment could have
benefits in terms of longer term mortality reductions.
Future studies need to focus on identifying the barriers
Table 4 Crude and adjusted hazard ratios of death and
loss to follow up stratified by missed visit status among
ART patients in Johannesburg, South Africa (n = 4476)
Visit type No.
Events
(%)
Person
time
(years)
Rate (per
100
person
years)
Crude HR
(95% CI)
Adjusted
HR‡
(95% CI)
Death
§
Medical
visits
0 76 (2.3%) 3080.6 2.5 Reference Reference
1 28 (2.7%) 984.4 2.8 1.15 (0.75-
1.78)
1.11 (0.72-
1.72)
2 8 (4.9%) 152.2 5.3 2.12 (1.03-
4.40)
2.06 (1.00-
4.28)
≥ 3 3 (15.0%) 15.7 19.1 7.69 (2.43-
24.4)
4.74 (1.39-
16.2)
ARV visits
0 90 (2.6%) 3309.3 2.7 Reference Reference
1 23 (2.7%) 806.5 2.9 1.05 (0.66-
1.66)
1.02 (0.65-
1.62)
2 0 (0%) 107.8 0 - -
≥ 3 2 (18.2%) 9.3 21.5 7.87 (1.94-
32.0)
8.15 (1.97-
33.7)
Lost to follow up
^
Medical
visits
0 196
(6.0%)
3080.6 6.4 Reference Reference
1 62 (5.9%) 984.4 6.3 0.99 (0.75-
1.32)
0.97 (0.73-
1.30)
2 15 (9.1%) 152.2 9.9 1.55 (0.92-
2.63)
1.54 (0.91-
2.61)
≥ 3 4 (22.0%) 15.7 25.5 4.07 (1.51-
10.9)
2.98 (1.10-
8.14)
ARV visits
0 196
(5.6%)
3309.3 5.9 Reference Reference
1 57 (6.6%) 806.5 7.1 1.20 (0.89-
1.61)
1.20 (0.89-
1.61)
22 4
(19.8%)
107.8 22.3 3.80 (2.48-
5.80)
3.81 (2.48-
5.84)
≥ 3 0 (0%) 9.3 0 - -
‡ Hazard ratios (HR) are from a Cox proportional regression models adjusted
for age, sex, total number of scheduled visits, baseline regimen and CD4
count after nine months on ART
§ Death obtained from South African National Vital Registration Infrastructure
Initiative
^Lost to follow up defined as ≥4 months since last visit
CI, confidence interval
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Page 8 of 10to adhering to a visit schedule so that interventions and
support services can be directed at those at risk.
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